dc.contributor.author | Bredin, Hanna Kosberg | |
dc.contributor.author | Krakstad, Camilla | |
dc.contributor.author | Høivik, Erling André | |
dc.date.accessioned | 2023-05-24T09:20:34Z | |
dc.date.available | 2023-05-24T09:20:34Z | |
dc.date.created | 2023-04-16T13:49:19Z | |
dc.date.issued | 2023-03-21 | |
dc.identifier.issn | 1932-6203 | |
dc.identifier.uri | https://hdl.handle.net/11250/3068797 | |
dc.description.abstract | Several studies have highlighted the frequent alterations of the PI3K pathway in endometrial cancer leading to increased signaling activation with potential for targeted treatment. The objective of this meta-study was to evaluate how PIK3CA exon 9/20 mutations affect survival in endometrial cancer patients, based on available literature. Topic-based search strategies were applied to databases including CENTRAL, MEDLINE, Embase, Web of Science and COSMIC. All studies assessing the impact of mutations in exon 9 and exon 20 of PIK3CA on survival rates of endometrial cancer patients were selected for inclusion. Statistical meta-analysis was performed with the ‘meta’ package in RStudio. Overall, 7 of 612 screened articles were included in the present study, comprising 1098 women with endometrial cancer. Meta-analysis revealed a tendency of impaired survival for patients with PIK3CA exon 9 and/or exon 20 mutations (RR 1.28; 95% CI 0.84, 1.94; p = 0.25). This tendency was consistent in subgroup analyses stratified by histologic type or -grade, with the most prominent effect in low-grade endometrial cancers (RR 2.04; 95% CI 0.90, 4.62; p = 0.09). In summary, these results suggest that PIK3CA mutations negatively influence survival outcomes of patients with endometrial cancer, including those with low-grade tumors. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | PLoS | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | PIK3CA mutations and their impact on survival outcomes of patients with endometrial cancer: A systematic review and meta-analysis | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2023 the authors | en_US |
dc.source.articlenumber | e0283203 | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.doi | 10.1371/journal.pone.0283203 | |
dc.identifier.cristin | 2141067 | |
dc.source.journal | PLOS ONE | en_US |
dc.identifier.citation | PLOS ONE. 2023, 18 (3), e0283203. | en_US |
dc.source.volume | 18 | en_US |
dc.source.issue | 3 | en_US |